9th Complement-Based Drug Development Summit
Media Partnership
between Fibrosis and 9th Complement-Based Drug Development Summit
So far, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis, Annexon Biosciences and Omeros, are making significant clinical progress in PNH, AMD, IgAN and C3G, whilst key academics such as Michael Holers, Michael Brenner, and Brahm Segal continue to make discoveries in complement imaging, novel pathways, and new therapeutics areas such as oncology and transplantation.
The Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront.
This comprehensive program spans a broad spectrum of renal, ophthalmic, neurological, and haematological indications, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations.
Join 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.
Find out more here: https://ter.li/cq44n6
